Home » Stocks » ALXN

Alexion Pharmaceuticals, Inc. (ALXN)

Stock Price: $181.65 USD -0.34 (-0.19%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $181.13 -0.52 (-0.29%) Jun 11, 6:34 PM
Market Cap 40.15B
Revenue (ttm) 6.26B
Net Income (ttm) 681.80M
Shares Out 220.10M
EPS (ttm) 3.08
PE Ratio 58.96
Forward PE 13.81
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $181.65
Previous Close $181.99
Change ($) -0.34
Change (%) -0.19%
Day's Open 181.95
Day's Range 181.21 - 182.72
Day's Volume 1,306,386
52-Week Range 99.91 - 182.72

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Investors seem to think that a drug from fledgling biotech Apellis Pharmaceuticals ( APLS , Financial) can go head-to-head with established treatments backed by a competitor 10 times its size.

Other stocks mentioned: APLS
2 days ago - GuruFocus

The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.

4 days ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

5 days ago - Business Wire

AstraZeneca PLC (LON:AZN) announced it has appointed Aradhana Sarin as an executive director and chief financial officer, effective from 1 August. The appointment is conditional on the success of the US...

Other stocks mentioned: AZN
1 week ago - Proactive Investors

Drugmaker AstraZeneca Plc said on Friday it had appointed Alexion's Aradhana Sarin as its new chief financial officer to succeed Marc Dunoyer who would be taking up a new role within the company.

Other stocks mentioned: AZN
1 week ago - Reuters

EU antitrust regulators will decide by July 5 whether to clear Anglo-Swedish drugmaker AstraZeneca's $39 billion bid for U.S.-based Alexion, a European Commission filing showed on Tuesday.

Other stocks mentioned: AZN
1 week ago - Reuters

AstraZeneca PLC (LON:AZN) announced it has priced €800mln (£691mln) of fixed-rate notes related to the proposed acquisition of Alexion Pharmaceuticals, Inc. They have a coupon of 0.375% maturing in 2029...

Other stocks mentioned: AZN
2 weeks ago - Proactive Investors

AstraZeneca PLC's (LON:AZN) proposed US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc. is now under investigation by the Competition and Markets Authority (CMA).

Other stocks mentioned: AZN
2 weeks ago - Proactive Investors

The U.K. competition regulator is mulling over AstraZeneca Plc's (NASDAQ: AZN) $39 billion takeover taker of Alexion Pharmaceuticals Inc (NASDAQ: ALXN) over competition concern. The U.K.'s Competition a...

Other stocks mentioned: AZN
2 weeks ago - Benzinga

AstraZeneca PLC's (LON:AZN) proposed US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc. is now under investigation by the Competition and Markets Authority (CMA).

Other stocks mentioned: AZN
2 weeks ago - Proactive Investors

Britain's competition regulator said on Tuesday it was probing if AstraZeneca's $39 billion takeover of U.S. drugmaker Alexion could reduce competition for products and services in the country or elsewh...

Other stocks mentioned: AZN
2 weeks ago - Reuters

BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--Alexion announces upcoming data presentations at the 26th European Hematology Association virtual Congress

1 month ago - Business Wire

BOSTON--(BUSINESS WIRE)--Alexion Shareholders Approve Acquisition by AstraZeneca

1 month ago - Business Wire

These could be the perfect stocks to own if a runaway bull market takes shape under the Biden administration.

Other stocks mentioned: AZN, GOOG, GOOGL, MA, TRUP
1 month ago - The Motley Fool

Elfun Trusts (Trades, Portfolio), part of Boston-based State Street Global Advisors, disclosed this week that its top five trades during the first quarter included a new position in Regions Financial Co...

Other stocks mentioned: AMAT, APD, FRC, RF
1 month ago - GuruFocus

Alexion (ALXN) delivered earnings and revenue surprises of 14.29% and 4.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Alexion (ALXN) tops earnings and sales in the first quarter of 2021. Its merger with AstraZeneca is expected to close in the third quarter.

Other stocks mentioned: AZN
1 month ago - Zacks Investment Research

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) moved higher by 2.2% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 9.32% year over year to $3.52,...

1 month ago - Benzinga

BOSTON--(BUSINESS WIRE)--Alexion Reports First Quarter 2021 Results

1 month ago - Business Wire

Alexion Pharmaceuticals (NASDAQ:ALXN) unveils its next round of earnings this Friday, April 30. Here is Benzinga's everything-that-matters guide for the earnings announcement.

1 month ago - Benzinga

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financia...

1 month ago - Business Wire

Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

With the trading day about halfway over, each of the major averages had notched a solid gain and was holding just below its respective all-time high.

Other stocks mentioned: ATVI, BKR, BMRN, ESPR, FATE, FLXN, RETA
1 month ago - 24/7 Wall Street

Alexion (ALXN) is set to provide updates on revenues and earnings when it releases first-quarter 2021 results on May 3.

1 month ago - Zacks Investment Research

Alexion Pharmaceuticals (ALXN) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

1 month ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financia...

1 month ago - Business Wire

AstraZeneca (AZN) obtains U.S. Federal Trade Commission's permission for the Alexion acquisition. The deal is expected to close in the third quarter of 2021.

Other stocks mentioned: AZN
1 month ago - Zacks Investment Research

Alexion (ALXN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

1 month ago - Zacks Investment Research

AstraZeneca PLC (LON:AZN) said its planned acquisition of rare disease specialist Alexion Pharmaceuticals Inc has been cleared by the US Federal Trade Commission. The FTSE 100 pharma giant said the appr...

Other stocks mentioned: AZN
1 month ago - Proactive Investors

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Other stocks mentioned: ABBV, ACAD, AZN, BIIB, BNTX, CRSP, EDIT ...
2 months ago - Investors Business Daily

Patient investors can make bank from these well-run businesses.

Other stocks mentioned: AZN, FB
2 months ago - The Motley Fool

With the trading day about halfway over, the broad markets had pulled back slightly.

Other stocks mentioned: DKNG, GSK, LUV, NFLX, BURL, INO, MDB ...
2 months ago - 24/7 Wall Street

AstraZeneca stock jumped Tuesday after the company reaffirmed its plan to acquire Alexion Pharmaceuticals in the third quarter, even as more European countries suspended use of its Covid vaccine. The po...

Other stocks mentioned: AZN
2 months ago - Investors Business Daily

NEW YORK, March 12, 2021 /PRNewswire/ --                                         If you own shares in any of the companies listed above and                             would like to discuss our investig...

Other stocks mentioned: BRPA, KTYB
3 months ago - PRNewsWire

Alexion (ALXN) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Alexion announces upcoming data presentations at the 73rd annual meeting of the American Academy of Neurology.

3 months ago - Business Wire

NEW YORK, Feb. 26, 2021 /PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or...

Other stocks mentioned: BRPA, STPK
3 months ago - PRNewsWire

The Nasdaq dropped 3.52% on Feb 25 for its worst session since October on rising rate worries. However, some stocks still remained in the green on that day or lost little.

Other stocks mentioned: ATVI, CSCO, MDLZ, MRNA, TMUS
3 months ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)---- $ALXN #Alexionpharmaceuticals--Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals

3 months ago - Business Wire

Paulson & Co., the firm led by John Paulson (Trades, Portfolio), disclosed this week that its top five buys during the fourth quarter of 2020 were in Horizon Therapeutics PLC (NASDAQ:HZNP), Barrick Gold...

Other stocks mentioned: GOLD, HZNP, RP, THRY
3 months ago - GuruFocus

Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Sanmina Corporation (SANM), Canadian Solar (CSIQ), Celestica (CLS) and Alexion Pharmaceuticals (ALXN...

Other stocks mentioned: CLS, CSIQ, SANM
4 months ago - Zacks Investment Research

ALXN vs. BMRN: Which Stock Is the Better Value Option?

Other stocks mentioned: BMRN
4 months ago - Zacks Investment Research

Here are five of the 61 value stocks with discounted PEG.

Other stocks mentioned: ACI, AGCO, PPC, PVH
4 months ago - Zacks Investment Research

Top Ranked Growth Stocks to Buy for February 10th

Other stocks mentioned: ACM, FLEX, MXL
4 months ago - Zacks Investment Research

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.

Other stocks mentioned: AMGN, BBH, BIIB, GILD, IBB, XBI
4 months ago - Zacks Investment Research

Alexion Pharmaceuticals (ALXN) beats earnings and sales estimates for the fourth quarter of 2020.

4 months ago - Zacks Investment Research

Alexion (ALXN) delivered earnings and revenue surprises of 18.40% and 5.70%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

BOSTON--(BUSINESS WIRE)--Alexion Reports Fourth Quarter and Full Year 2020 Results

4 months ago - Business Wire

Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

About ALXN

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq for patients with hypophosphatasia; Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency; and Andexxa, a reversal agent for ... [Read more...]

Industry
Biotechnology
IPO Date
Feb 28, 1996
CEO
Leonard Bell
Employees
3,837
Stock Exchange
NASDAQ
Ticker Symbol
ALXN
Full Company Profile

Financial Performance

In 2020, ALXN's revenue was $6.07 billion, an increase of 21.61% compared to the previous year's $4.99 billion. Earnings were $603.40 million, a decrease of -74.90%.

Financial Statements

Analyst Forecasts

According to 18 analysts, the average rating for ALXN stock is "Hold." The 12-month stock price forecast is 177.36, which is a decrease of -2.36% from the latest price.

Price Target
$177.36
(-2.36% downside)
Analyst Consensus: Hold